Genentech update on phase III study of Tecentriq + Avastin in women with advanced-stage ovarian cancer.
Genentech, a member of the Roche Group announced that the Phase III IMagyn050 study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did… read more.